Actively Recruiting
Detection of Minimal Residual Disease Post-prostatectomy
Led by Radboud University Medical Center · Updated on 2026-01-12
50
Participants Needed
1
Research Sites
119 weeks
Total Duration
On this page
Sponsors
R
Radboud University Medical Center
Lead Sponsor
C
Catharina Ziekenhuis Eindhoven
Collaborating Sponsor
AI-Summary
What this Trial Is About
The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.
CONDITIONS
Official Title
Detection of Minimal Residual Disease Post-prostatectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male aged 18 years or older
- High-risk localized prostate cancer with PSA >20 ng/mL, Gleason score 8-10 (ISUP grade 4/5), or stage iT3a by prostate MRI
- High-risk locally advanced prostate cancer with any PSA level, any Gleason score/ISUP grade, stage iT3b-4 by prostate MRI or iN1 by PSMA PET/CT
- Scheduled for robot-assisted radical prostatectomy
- Willing to consent to tissue and liquid biobanking
You will not qualify if you...
- Relevant contra-indications limiting clinical follow-up or blood collection as judged by the physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prosper Prostate Cancer Clinics
Nijmegen, Netherlands
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here